May 21, 2012
Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a developer of oral delivery systems, announced today that it was chosen to present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference taking place in
May 21-23, 2012
. The presentation will be given by
, Oramed's President and CEO, on
Wednesday, May 23rd
(IDT) during the BioPharma Session.
National Life Science & Technology Week ILSI-BIOMED Conference
David InterContinental Hotel,
Wednesday, May 23, 2012
12:10 p.m. (IDT), or 5:10 a.m. (EST)
For more information on the upcoming ILSI Biomed conference, please visit their website:
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at
Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials, and with its GLP-1 analog capsule, currently entering Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.
For more information, the content of which is not part of this press release, please visit
Safe Harbor for
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Included therein are the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward-looking statements. The company undertakes no obligation to update or revise any forward-looking statements.
Company and Investor Relations Contact: Oramed Pharmaceuticals
USA: +1-646-240-4193 Int'l: +972-2-566-0001 +972-54-792-4438 E-mail:
SOURCE Oramed Pharmaceuticals Inc.